Available modeling studies show RRSO and/or RRM are cost-effective compared with BC surveillance or no surgery for BRCA1 and BRCA2, while the ages at surgery varied.26,27,28 To our knowledge, no cost-effectiveness studies for non-BRCA CSG PV carriers (ie, PALB2, RAD51C, RAD51D, or BRIP1) have been undertaken.26,27,28 Additionally, UK health system RRSO and RRM–specific cost-effectiveness data are lacking for BRCA1 and BRCA2. The gene discussed is RAD51D; the disease is breast cancer.